Evidence map›Paper›PMID 39361182›Full record

ArticleClinical and experimental nephrology2025

Annual change in eGFR in renal hypouricemia: a retrospective pilot study.

Shinobu Sugihara, Yasutaka Yamamoto, Kei Teramoto, Toshiro Hamada, Satoshi Miyazaki, Kazuhide Ogino, Masanari Kuwabara, Akira Ohtahara, Einosuke Mizuta, Kimiyoshi Ichida and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shinobu SugiharaMatsue Health Service Center, Shimane University, Matsue, Japan. shinobutozuito@gmail.com.ORCID http://orcid.org/0000-0003-1386-3254
Yasutaka YamamotoYasutaka Yamamoto Cardiology/Internal Medicine Clinic, Fuji, Japan.
Kei TeramotoThe Division of Medical Informatics, Tottori University Hospital, Tottori, Japan.
Toshiro HamadaDepartment of Community-Based Family Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Satoshi MiyazakiDivision of Cardiology, Fujii Masao Memorial Hospital, Kurayoshi, Japan.
Kazuhide OginoDepartment of Cardiology, Japanese Red Cross Tottori Hospital, Tottori, Japan.
Masanari KuwabaraDepartment of Cardiology, Toranomon Hospital, Tokyo, Japan.
Akira OhtaharaDepartment of Cardiology, Sanin Rosai Hospital, Yonago, Japan.
Einosuke MizutaDepartment of Cardiology, Sanin Rosai Hospital, Yonago, Japan.
Kimiyoshi IchidaDepartment of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Yusuke EndoAdvanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Yonago, Japan.
Hiroyuki MinatoDepartment of Anesthesiology, Faculty of Medicine, Tottori University, Yonago, Japan.
Haruaki NinomiyaDepartment of Biological Regulation, Tottori University, Yonago, Japan.
Masahiko KatoDivision of School of Health Science, Department of Pathobiological Science and Technology, Faculty of Medicine, Tottori University, Yonago, Japan.
Kazuhiro YamamotoDepartment of Cardiovascular Medicine and Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Yonago, Japan.
Ichiro HisatomeDepartment of Cardiology, National Hospital Organization, Yonago Medical Center, Yonago, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExtremely low uric acid (UA) levels or increased urinary UA (Uua) excretion might be risk factors for kidney disease in renal hypouricemia (RHU) patients, but their relationship with kidney dysfunction is unclear. This study investigated time-dependent changes in eGFR in RHU patients.

methodsThis multicenter retrospective study assessed UA metabolism and changes in eGFR (median 5.5 years) in 13 RHU patients. We then compared eGFR change in 7 of 13 RHU patients whose eGFR could be measured for 4 years with those in normouricemic group (n = 31). In addition, 7 RHU patients were divided into two groups based on URAT1 gene mutations: homozygote and compound heterozygote mutations (Homo/Com group, n = 3), and wild-type and heterogeneous mutations (WT/Hetero group, n = 4).

resultsIn 13 RHU patients, the median and mean serum UA (SUA) were 0.8 (0.4-2.5) and 1.1 ± 0.7 mg/dL. The median and mean Uua were 44.3 (12.7-141.1) and 49.7 ± 36.2 mg/dL. The median and mean urinary urate clearance (Cua/Ccr) were 46.8 (11.3-73.6) and 43.3 ± 19.7%. Over 4 years, eGFR did not change in the RHU group but declined in the normouricemic group. Annual mean eGFR decline and change rate in the RHU group were the same as those in the normouricemic group (- 1.09 ± 1.11 vs. - 1.09 ± 1.92 mL/min/1.73 m

conclusionRHU from URAT1 genetic mutation may not show eGFR decline over 4 consecutive years.

Indexed as

Glomerular Filtration RateKidneyRenal Tubular Transport, Inborn ErrorsUric AcidAdultAgedErbB ReceptorsFemaleHumansMaleMiddle AgedMutationOrganic Anion TransportersOrganic Cation Transport ProteinsPilot ProjectsRetrospective StudiesEGFR protein, humanErbB ReceptorsOrganic Anion TransportersOrganic Cation Transport ProteinsSLC22A12 protein, humanUric AcideGFRKidney dysfunctionRenal hypouricemiaURAT1 gene mutation

Identifiers

PMID39361182
PMCPMC11828821

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.